Ningbo MedicalSystem Biotechnology Co Ltd Cash Flow Conversion Efficiency
Ningbo MedicalSystem Biotechnology Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Ningbo MedicalSystem Biotechnology Co Ltd (300439) has a cash flow conversion efficiency ratio of 0.017x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥48.96 Million ≈ $7.16 Million USD) by net assets (CN¥2.95 Billion ≈ $431.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ningbo MedicalSystem Biotechnology Co Ltd (2011–2024)
Cash flow conversion efficiency of Ningbo MedicalSystem Biotechnology Co Ltd from 2011 to 2024. This chart illustrates how Ningbo MedicalSystem Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ningbo MedicalSystem Biotechnology Co Lt (300439) share price today for real-time trading data and today's change.
Ningbo MedicalSystem Biotechnology Co Ltd Cash Flow Conversion Ratio Explained
Ningbo MedicalSystem Biotechnology Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ningbo MedicalSystem Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ningbo MedicalSystem Biotechnology Co Ltd ranked by their cash flow conversion efficiency. Also see 300439 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-C
|
1.189x |
|
Pepper Money Ltd
AU:PPM
|
-1.010x |
|
Beijing Bayi Space LCD Technology Co Ltd
SHG:688181
|
0.057x |
|
Baotou Huazi Industry Co Ltd
SHG:600191
|
0.016x |
|
Amos Luzon Development and Energy Group Ltd
TA:LUZN
|
-0.013x |
|
Qingdao Liqun Department Store Group Co Ltd
SHG:601366
|
0.146x |
|
Hengyuan Refining Company Bhd
KLSE:4324
|
0.281x |
|
Matas A/S
CO:MATAS
|
0.111x |
Annual Cash Flow Conversion Efficiency for Ningbo MedicalSystem Biotechnology Co Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Ningbo MedicalSystem Biotechnology Co Ltd from 2011 to 2024. Review 300439 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.93 Billion ≈ $429.26 Million |
CN¥397.81 Million ≈ $58.21 Million |
0.136x | -42.06% |
| 2023-12-31 | CN¥2.71 Billion ≈ $396.07 Million |
CN¥633.53 Million ≈ $92.71 Million |
0.234x | +4.43% |
| 2022-12-31 | CN¥2.52 Billion ≈ $368.67 Million |
CN¥564.67 Million ≈ $82.63 Million |
0.224x | +3.95% |
| 2021-12-31 | CN¥2.39 Billion ≈ $349.84 Million |
CN¥515.48 Million ≈ $75.43 Million |
0.216x | -60.12% |
| 2020-12-31 | CN¥1.69 Billion ≈ $246.86 Million |
CN¥912.07 Million ≈ $133.47 Million |
0.541x | +24.86% |
| 2019-12-31 | CN¥1.39 Billion ≈ $203.16 Million |
CN¥601.17 Million ≈ $87.97 Million |
0.433x | +134.69% |
| 2018-12-31 | CN¥2.27 Billion ≈ $332.15 Million |
CN¥418.80 Million ≈ $61.28 Million |
0.185x | +428.61% |
| 2017-12-31 | CN¥2.29 Billion ≈ $334.63 Million |
CN¥-128.40 Million ≈ $-18.79 Million |
-0.056x | -4283.55% |
| 2016-12-31 | CN¥1.83 Billion ≈ $267.53 Million |
CN¥2.45 Million ≈ $359.05K |
0.001x | -99.03% |
| 2015-12-31 | CN¥1.29 Billion ≈ $188.39 Million |
CN¥177.55 Million ≈ $25.98 Million |
0.138x | -50.86% |
| 2014-12-31 | CN¥415.13 Million ≈ $60.75 Million |
CN¥116.51 Million ≈ $17.05 Million |
0.281x | -13.52% |
| 2013-12-31 | CN¥308.32 Million ≈ $45.12 Million |
CN¥100.06 Million ≈ $14.64 Million |
0.325x | +40.55% |
| 2012-12-31 | CN¥202.58 Million ≈ $29.64 Million |
CN¥46.78 Million ≈ $6.85 Million |
0.231x | -48.63% |
| 2011-12-31 | CN¥110.84 Million ≈ $16.22 Million |
CN¥49.82 Million ≈ $7.29 Million |
0.450x | -- |
About Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass… Read more